Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-Year results of the APACC randomised trial

Gut

Volumn 61, Issue 2, 2012, Pages 255-261

  Benamouzig, Robert ^a   Uzzan, Bernard ^a   Deyra, Jacques ^b   Martin, Antoine ^a   Girard, Bernard ^b   Little, Julian ^c   Chaussade, Stanislas ^d  

^a AVICENNE HOSPITAL   (France)

^b APACC Coordination Centre   (France)

^c UNIVERSITY OF OTTAWA   (Canada)

^d université Paris Cité   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LYSINE ACETYLSALICYLATE; PLACEBO;

ADENOMATOUS POLYP; ADULT; ARTICLE; BLEEDING; COLONOSCOPY; COLORECTAL ADENOMA; CONTROLLED STUDY; DISEASE ACTIVITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; STROKE; TREATMENT DURATION; TUMOR RECURRENCE; TUMOR VOLUME;

ADENOMA; ADENOMATOUS POLYPS; AGED; ASPIRIN; COLONOSCOPY; COLORECTAL NEOPLASMS; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYSINE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECURRENCE; TREATMENT OUTCOME;

EID: 84855191820     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-300113     Document Type: Article

References (82)

1. IARC Working Group on the Evaluation of Cancer Preventive Agents. Non-Steroidal Anti-Inflammatory Drugs. Lyon: International Agency for Research on Cancer. World Health Organisation, 1997.
2. La Vecchia C, Negri E, Franceschi S, et al. Aspirin and colorectal cancer. Br J Cancer 1997;76:675-7. (Pubitemid 27354684)
3. Neugut AI, Rosenberg DJ, Ahsan H, et al. Association between coronary heart disease and cancers of the breast, prostate and colon. Cancer Epidemiol Biomarkers Prev 1998;7:869-73. (Pubitemid 28471574)
4. Smalley W, Ray WA, Daugherty J, et al. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med 1999;159:161-6. (Pubitemid 29055104)
5. Collet JP, Sharpe C, Belzile E, et al. Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br J Cancer 1999;81:62-8. (Pubitemid 29415492)
6. Langman MJ, Cheng KK, Gilman EA, et al. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000;320:1642-6. (Pubitemid 30364636)
7. Coogan PF, Rosenberg L, Louik C, et al. NSAIDs and risk of colorectal cancer according to presence or absence of family history of the disease. Cancer Causes Control 2000;11:249-55. (Pubitemid 30182142)
8. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illness, operations and medications: case-control results from the Melbourne Colorectal Cancer Study. Cancer Res 1998;48:4399-404.
9. Giovannucci E, Rimm EB, Stampfer MJ, et al. Aspirin use and the risk for colorectal cancer adenoma in male health professionals. Ann Intern Med 1994;121:241-6.
10. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609-14.
11. Muller AD, Sonnenberg A, Wasseman IH. Diseases preceeding colon cancer. A case control study among veterans. Dig Dis Sci 1994;39:2480-4. (Pubitemid 24350034)
12. Peleg II, Maibach HT, Brown SH, et al. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 1994;154:394-9. (Pubitemid 24072212)
13. Chan AT, Giovannucci EL, Meyerhardt JA, et al. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005;294:914-23. (Pubitemid 41215460)
14. Chan AT, Giovannucci EL, Meyerhardt JA, et al. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology 2008;134:21-8. (Pubitemid 350309311)
15. Flossmann E, Rothwell PM; on behalf of the British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007;369:1603-13. (Pubitemid 46710123)
16. Cuzick J, Otto F, Baron JA, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 2009;10:501-7.
17. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009;302:649-59.
18. Baron JA. Intermediate effect markers for colorectal cancer. IARC Sci Publ 2001;154:113-29.
19. Dubé C, Rostom A, Lewin G, et al.; US Preventive Services Task Force. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the US preventive services task force. Ann Intern Med 2007;146:365-75. (Pubitemid 351650597)
20. Benamouzig R. [Do aspirin or nonsteroidal anti-inflammatory drugs decrease the risk of colorectal cancer?] (In French). Gastroenterol Clin Biol 1998;22(3 Suppl): S22-7.
21. Li H, Schut HA, Conran P, et al. Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin -2 levels in rat colon. Carcinogenesis 1999;20:425-30. (Pubitemid 29112630)
22. Gann PH, Manson JE, Glynn RJ, et al. Low-dose aspirin use and incidence of colorectal tumors in a randomised trial. J Natl Cancer Inst 1993;85:1120-4.
23. Sturmer T, Glynn RJ, Lee IM, et al. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann Intern Med 1998;128:713-20. (Pubitemid 28204862)
24. Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomised controlled trial. JAMA 2005;294:47-55. (Pubitemid 41002838)
25. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ (Clin Res Ed) 1988;296:313-16. (Pubitemid 18042841)
26. Farrell B, Godwin J, Richards S, et al. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991;54:1044-54.
27. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010;376:1741-50.
28. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90. Erratum in N Engl J Med 2003;348:1939. (Pubitemid 36297996)
29. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9. (Pubitemid 36297997)
30. Logan RF, Grainge MJ, Shepherd VC, et al. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 2008;134:29-38. (Pubitemid 350309319)
31. Leshno M, Moshkowitz M, Arber N. Aspirin is clinically effective in chemoprevention of colorectal neoplasia: point. Cancer Epidemiol Biomarkers Prev 2008;17:1558-61.
32. Sandler RS. Aspirin should not be promoted for colon cancer prevention: counterpoint. Cancer Epidemiol Biomarkers Prev 2008;17:1562-3.
33. Benamouzig R, Deyra J, Martin A, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: One-year results of the APACC trial. Gastroenterology 2003;125:328-36. (Pubitemid 36929412)
34. Benamouzig R, Yoon H, Little J, et al.; APACC Study Group. Association pour la Prevention par Aspirine du Cancer Colorectal. APACC, a French prospective study on aspirin efficacy in reducing colorectal adenoma recurrence: design and baseline findings. Eur J Cancer Prev 2001;10:327-35. (Pubitemid 32735349)
35. Rex DK, Cutler CS, Lemmel GT, et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology 1997;112:24-8. (Pubitemid 27008981)
36. Bensen S, Mott LA, Dain B, et al. The colonoscopic miss rate and true one-year recurrence of colorectal neoplastic polyps. Polyp Prevention Study Group. Am J Gastroenterol 1999;94:194-9. (Pubitemid 29063468)
37. Miliaras S, Miliaras D, Vrettou E, et al. The effect of aspirin and high fibre die ton colorectal carcinoma: a comparative experimental study. Tech Coloproctol 2004;8(Suppl 1):s59-61. (Pubitemid 40394515)
38. Reddy BS, Rao CV, Rivenson A, et al. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 1993;14:1493-7. (Pubitemid 23249348)
39. Cole BF, Logan RF, Halabi S, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 2009;101:256-66.
40. Burn J, Bishop DT, Mecklin JP, et al.; CAPP2 Investigators. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med 2008;359:2567-78.
41. Giardiello FM, Yang VW, Hylind LM, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002;346:1054-9. (Pubitemid 34984619)
42. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52. (Pubitemid 30419089)
43. Arber N, Eagle CJ, Spicak J, et al.; PreSAP Trial Investigators. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885-95. (Pubitemid 44315981)
44. Baron JA, Sandler RS, Bresalier RS, et al.; APPROVe Trial Investigators. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006;131:1674-82. (Pubitemid 44958508)
45. Bertagnolli M, Eagle CJ, Zauber AG, et al.; APC Study Investigators. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84. (Pubitemid 44315980)
46. Wishingrad M, Titzer D, Triadafilopoulos G, et al. Chronic aspirin and NSAID use may protect against colorectal adenomas. Gastroenterology 1994;112:A452.
47. Macrae FA, Russell A, MacLennan R. Aspirin effects on large adenomas. Gastroenterology 1994;112:A413.
48. Tosteson T, Greenberg E, Baron J. Aspirin use and reduced occurence of large bowel adenomas. Gastroenterology 1995;108:A39.
49. Garcia Rodriguez LA, Huerta-Alvarez C. Reduced incidence of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs: a pooled analysis of published studies and a new population-based study. Epidemiology 2000;11:376-81. (Pubitemid 30428928)
50. Breuer-Katschinski B, Nemes K, Rump B, et al. Long-term use of nonsteroidal antiinflammatory drugs and the risk of colorectal adenomas. The Colorectal Adenoma Study Group. Digestion 2000;61:129-34. (Pubitemid 30114080)
51. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-8. (Pubitemid 24294584)
52. Sano H, Kawahito Y, Wilder RL, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995;55:3785-9.
53. Fujita T, Matsui M, Takaku K, et al. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 1998;58:4823-6. (Pubitemid 28503676)
54. Sheehan KM, Sheahan K, O'Donoghue DP, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999;282:1254-7.
55. Dimberg J, Samuelsson A, Hugander A, et al. Differential expression of cyclooxygenase 2 in human colorectal cancer. Gut 1999;45:730-2. (Pubitemid 29492147)
56. Hao X, Bishop AE, Wallace M, et al. Early expression of cyclo-oxygenase-2 during sporadic colorectal carcinogenesis. J Pathol 1999;187:295-301. (Pubitemid 29064154)
57. Masunaga R, Kohno H, Dhar DK, et al. Cycooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000;6:4064-8.
58. Tomozawa S, Tsuno NH, Sunami E, et al. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 2000;83:324-8. (Pubitemid 30453571)
59. Cianchi F, Cortesini C, Bechi P, et al. Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 2001;121:1339-47. (Pubitemid 33140451)
60. Zhang H, Sun XF. Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am J Gastroenterol 2002;97:1037-41. (Pubitemid 34408266)
61. Yamauchi T, Watanabe M, Kubota T, et al. Cyclooxygenase-2 expression as a new marker for patients with colorectal cancer. Dis Colon Rectum 2002;45:98-103. (Pubitemid 34072758)
62. Joo YE, Kim HS, Min SW, et al. Expression of cyclooxygenase-2 protein in colorectal carcinomas. Int J Gastrointest Cancer 2002;31:147-54.
63. Wu AW, Gu J, Li ZF, et al. Role of COX-2 in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients' prognosis. World J Gastroenterol 2003;9:1990-4. (Pubitemid 37168428)
64. Soumaoro LT, Uetake H, Higuchi T, et al. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 2004;10:8465-71. (Pubitemid 40053411)
65. Chapple KS, Cartwright EJ, Hawcroft G, et al. Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. Am J Pathol 2000;156:545-53. (Pubitemid 30643810)
66. Khan KN, Masferrer JL, Woerner BM, et al. Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon. Scand J Gastroenterol 2001;36:865-9. (Pubitemid 32656562)
67. Hasegawa K, Ichikawa W, Fujita T, et al. Expression of cyclooxygenase-2 (COX-2) mRNA in human colorectal adenomas. Eur J Cancer 2001;37:1469-74. (Pubitemid 32744675)
68. Arao J, Sano Y, Fujii T, et al. Cyclooxygenase-2 is overexpressed in serrated adenoma of the colorectum. Dis Colon Rectum 2001;44:1319-23. (Pubitemid 32845911)
69. Elder DJ, Baker JA, Banu NA, et al. Human colorectal adenomas demonstrate a size-dependent increase in epithelial cyclooxygenase-2 expression. J Pathol 2002;198:428-34. (Pubitemid 35446995)
70. Azumaya M, Kobayashi M, Ajioka Y, et al. Size-dependent expression of cyclooxygenase-2 in sporadic colorectal adenomas relative to adenomas in patients with familial adenomatous polyposis. Pathol Int 2002;52:272-6. (Pubitemid 34587812)
71. Takeuchi M, Kobayashi M, Ajioka Y, et al. Comparison of cyclo-oxygenase 2 expression in colorectal serrated adenomas to expression in tubular adenomas and hyperplastic polyps. Int J Colorectal Dis 2002;17:144-9. (Pubitemid 36075765)
72. Einspahr JG, Krouse RS, Yochim JM, et al. Association between cyclooxygenase expression and colorectal adenoma characteristics. Cancer Res 2003;63:3891-3. (Pubitemid 36917900)
73. Adegboyega PA, Ololade O, Saada J, et al. Subepithelial myofibroblasts express cyclooxygenase-2 in colorectal tubular adenomas. Clin Cancer Res 2004;10:5870-9. (Pubitemid 39180968)
74. Tatsu K, Hayashi S, Shimada I, et al. Cyclooxygenase-2 in sporadic colorectal polyps: immunohistochemical study and its importance in the early stages of colorectal tumorigenesis. Pathol Res Pract 2005;201:427-33. (Pubitemid 41093720)
75. Pisano C, Ottaiano A, Tatangelo F, et al. Cyclooxygenase-2 expression is associated with increased size in human sporadic colorectal adenomas. Anticancer Res 2005;25:2065-8. (Pubitemid 40904605)
76. Kawasaki T, Nosho K, Ohnishi M, et al. Cyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma. BMC Cancer 2008;8:33.
77. Benamouzig R, Uzzan B, Martin A, et al. Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention. Gut 2010;59:622-9.
78. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007;356:2131-42. (Pubitemid 47010839)
79. Lai MY, Huang JA, Liang ZH, et al. Mechanisms underlying aspirin-mediated growth inhibition and apoptosis induction of cyclooxygenase-2 negative colon cancer cell line SW480. World J Gastroenterol 2008;14:4227-33.
80. Hanif R, Pittas A, Feng Y, et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996;52:237-45. (Pubitemid 26233752)
81. Yu HG, Huang JA, Yang YN, et al. The effects of acetylsalicylic acid on proliferation, apoptosis, and invasion of cyclooxygenase-2 negative colon cancer cells. Eur J Clin Invest 2002;32:838-46.
82. Winaver SJ, Zauber AG, Ho AN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993;329:1977-81. (Pubitemid 24015040)